Yusuke Hiratsuka1,2, Takayuki Oishi3, Mitsunori Miyashita4, Tatsuya Morita5, Jennifer W Mack6, Yuko Sato3, Masahiro Takahashi3, Keigo Komine7, Ken Saijo3, Chikashi Ishioka3, Akira Inoue2. 1. Department of Palliative Medicine, Takeda General Hospital, Aizu Wakamatsu, Japan. 2. Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan. 3. Department of Clinical Oncology, Tohoku University School of Medicine, Sendai, Japan. 4. Department of Palliative Nursing, Tohoku University School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan. miya@med.tohoku.ac.jp. 5. Department of Palliative and Supportive Care, Palliative Care Team, and Seirei Hospice, Seirei Mikatahara General Hospital, Hamamatsu, Japan. 6. Department of Pediatric Oncology and Center for Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA. 7. Department of Medical Oncology, Tohoku University Hospital, Sendai, Japan.
Abstract
PURPOSE: This study aimed to (1) describe characteristics of aggressive care at the end of life (EOL) and (2) identify factors associated with specialized palliative care use (SPC) and aggressive care at the EOL among Japanese patients with advanced cancer. METHODS: This single-center, follow-up cohort study involved patients with advanced cancer who received chemotherapy at Tohoku University Hospital. Patients were surveyed at enrollment, and we followed clinical events for 5 years from enrollment in the study. We performed multivariate logistic regression analysis to identify independent factors related to SPC use and chemotherapy in the last month before death. RESULTS: We analyzed a total of 135 patients enrolled between January 2015 and January 2016. No patients were admitted to the intensive care unit, and few received resuscitation or ventilation. We identified no factors significantly associated with SPC use. Meanwhile, younger age (20-59 years, odds ratio [OR] 4.10; 95% confidence interval [CI] 1.30-12.91; p = 0.02) and no receipt of SPC (OR 4.32; 95% CI 1.07-17.37; p = 0.04) were associated with chemotherapy in the last month before death. CONCLUSION: Younger age and a lack of SPC were associated with chemotherapy at the EOL in patients with advanced cancer in Japan. These findings suggest that Japanese patients with advanced cancer may benefit from access to SPC.
PURPOSE: This study aimed to (1) describe characteristics of aggressive care at the end of life (EOL) and (2) identify factors associated with specialized palliative care use (SPC) and aggressive care at the EOL among Japanese patients with advanced cancer. METHODS: This single-center, follow-up cohort study involved patients with advanced cancer who received chemotherapy at Tohoku University Hospital. Patients were surveyed at enrollment, and we followed clinical events for 5 years from enrollment in the study. We performed multivariate logistic regression analysis to identify independent factors related to SPC use and chemotherapy in the last month before death. RESULTS: We analyzed a total of 135 patients enrolled between January 2015 and January 2016. No patients were admitted to the intensive care unit, and few received resuscitation or ventilation. We identified no factors significantly associated with SPC use. Meanwhile, younger age (20-59 years, odds ratio [OR] 4.10; 95% confidence interval [CI] 1.30-12.91; p = 0.02) and no receipt of SPC (OR 4.32; 95% CI 1.07-17.37; p = 0.04) were associated with chemotherapy in the last month before death. CONCLUSION: Younger age and a lack of SPC were associated with chemotherapy at the EOL in patients with advanced cancer in Japan. These findings suggest that Japanese patients with advanced cancer may benefit from access to SPC.
Authors: Craig C Earle; Elyse R Park; Bonnie Lai; Jane C Weeks; John Z Ayanian; Susan Block Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544
Authors: Craig C Earle; Bridget A Neville; Mary Beth Landrum; Jeffrey M Souza; Jane C Weeks; Susan D Block; Eva Grunfeld; John Z Ayanian Journal: Int J Qual Health Care Date: 2005-06-28 Impact factor: 2.038
Authors: Julia M Langton; Bianca Blanch; Anna K Drew; Marion Haas; Jane M Ingham; Sallie-Anne Pearson Journal: Palliat Med Date: 2014-05-27 Impact factor: 4.762
Authors: Alexi A Wright; Nancy L Keating; John Z Ayanian; Elizabeth A Chrischilles; Katherine L Kahn; Christine S Ritchie; Jane C Weeks; Craig C Earle; Mary B Landrum Journal: JAMA Date: 2016-01-19 Impact factor: 56.272
Authors: Craig C Earle; Bridget A Neville; Mary Beth Landrum; John Z Ayanian; Susan D Block; Jane C Weeks Journal: J Clin Oncol Date: 2004-01-15 Impact factor: 44.544
Authors: Craig C Earle; Mary Beth Landrum; Jeffrey M Souza; Bridget A Neville; Jane C Weeks; John Z Ayanian Journal: J Clin Oncol Date: 2008-08-10 Impact factor: 44.544
Authors: Alexi A Wright; Baohui Zhang; Alaka Ray; Jennifer W Mack; Elizabeth Trice; Tracy Balboni; Susan L Mitchell; Vicki A Jackson; Susan D Block; Paul K Maciejewski; Holly G Prigerson Journal: JAMA Date: 2008-10-08 Impact factor: 56.272